Biomea Fusion, Inc. (BMEA) - Latest Market Data

Price & Market Data

Price: $1.42

Daily Change: +$0.05 / 3.52%

Daily Range: $1.30 - $1.46

Market Cap: $102,665,200

Daily Volume: 910,901

Performance Metrics

1 Week: 1.06%

1 Month: -26.03%

3 Months: 10.38%

6 Months: 46.43%

1 Year: 0.35%

YTD: 13.89%

About Biomea Fusion, Inc. (BMEA)

Financial summary for Biomea Fusion, Inc. (BMEA). Price: 1.42, daily change: +$0.05 / 3.52%. Market cap: 102,665,200. Performance for all periods at a glance.

Company Details

Employees: 41

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Selected stocks

Frontier Group Holdings, Inc. (ULCC)

ZK International Group Co., Ltd (ZKIN)

Chemomab Therapeutics Ltd. (CMMB)

Inotiv, Inc. (NOTV)

Nixxy, Inc. (NIXX)